Sunny days for Nimbus: Lilly inks $496M biobucks deal for potential metabolic disease therapies
Nimbus Therapeutics raises $125m to test drug in psoriasis, lupus, and other diseases
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
Nimbus clinches $125M raise via big donor-backed private financing round following Bristol Myers’ TYK2 approval
Nimbus Therapeutics Automates CRO Data Ingestion to Accelerate Deployment to Scientists
BIO: Nimbus CEO: ‘We’re not just a one-hit wonder’
Nimbus picks 4 preclinical targets for the next chapter of its pioneering computational drug discovery work
Celgene turns to Nimbus on ‘highly prized’ I/O target — landing right in Bristol-Myers’ sweet spot
Discovery of Allosteric Inhibition of Human ATP-Citrate Lyase
Nimbus exposes complete ACLY structure, discovers allosteric inhibitory sites
